Effects of cilostazol on risk of major amputation after endovascular therapy in haemodialysis patients with critical limb ischaemia

Trial Profile

Effects of cilostazol on risk of major amputation after endovascular therapy in haemodialysis patients with critical limb ischaemia

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Oct 2015

At a glance

  • Drugs Cilostazol (Primary)
  • Indications Peripheral ischaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Oct 2015 New trial record
    • 02 Sep 2015 Results presented at ESC Congress 2015: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top